[ANMCO Position paper: Diagnostic and therapeutic pathways in patients with hypercholesterolemia and statin intolerance].
Statins are a class of drugs registered and prescribed to lower total and LDL-cholesterol. Clinical trials performed in the last 25 years have shown that these agents are effective in improving cardiovascular outcomes in several different clinical settings. However, in some cases statin treatment may be associated with significant side effects and adverse reactions. The occurrence of such adverse events during statin therapy may cause discontinuation of treatment together with the impossibility of achieving recommended lipid goals. The clinical condition in which patients experience major unacceptable symptoms and/or develop laboratory abnormalities during statin therapy is defined as statin intolerance. This document outlines the diagnostic and therapeutic pathways for the clinical management of patients with hypercholesterolemia and statin intolerance.
U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania.
Michele Massimo
MM
Gulizia
U.O.C. Cardiologia, Presidio Ospedaliero San Filippo Neri, Roma.
Furio
F
Colivicchi
Centro Aterosclerosi, Policlinico Umberto I, Sapienza Università di Roma, Roma.
Marcello
M
Arca
U.O.C. Cardiologia, Ospedale Civile Sant'Antonio Abate, Erice (TP).
Maurizio Giuseppe
MG
Abrignani
U.O.C. Cardiologia, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", Ancona.
Gian Piero
GP
Perna
U.O.C. Cardiologia III, A.O. San Giovanni-Addolorata, Roma.
Gian Francesco
GF
Mureddu
U.O.C. Cardiologia, Ospedale Castelli, Verbania.
Federico
F
Nardi
U.O.C. Cardiologia e Riabilitazione Cardiologica, A.O. Sant'Anna e San Sebastiano, Caserta.
Carmine
C
Riccio
D000465:Algorithms; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D007558:Italy; D018570:Risk Assessment; D012307:Risk Factors
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors